Halozyme Therapeutics, Inc.
IT ˙ BIT ˙ US40637H1095
58,52 € 0,00 (0,00%)
2026-06-03
AKTIENPREIS
SecurityIT:1HALO / Halozyme Therapeutics, Inc.
InstitutionBlackRock, Inc.
Latest Disclosed Ownership12,612,300 shares
Ownership 10.20%
BlackRock, Inc. ownership in 1HALO / Halozyme Therapeutics, Inc.

2025-07-17 - BlackRock, Inc. has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 12,612,300 shares of Halozyme Therapeutics, Inc. (IT:1HALO). This represents 10.2 percent ownership of the company. In their previous filing dated 2025-04-28 , BlackRock, Inc. had reported owning 16,144,164 shares, indicating a decrease of -21.88 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2025-07-17 2025-07-17 13G/A 16,144,164 12,612,300 -21.88 10.20 -22.14
2025-04-28 2025-04-28 13G/A 18,629,818 16,144,164 -13.34 13.10 -7.09
2024-01-23 2024-01-23 13G/A 19,196,061 18,629,818 -2.95 14.10 -0.70
2023-02-10 2023-02-10 13G/A 18,214,071 19,196,061 5.39 14.20 4.41
2023-01-26 2023-01-26 13G/A 18,214,071 18,214,071 0.00 13.60 0.00
2023-01-20 2023-01-20 13G 19,439,863 18,214,071 -6.31 13.60 -1.45
2022-01-28 2022-01-28 13G/A 18,481,307 19,439,863 5.19 13.80 0.73
2021-01-26 2021-01-26 13G/A 18,684,130 18,481,307 -1.09 13.70 -0.72
2020-12-08 2020-12-08 13G 12,096,797 18,684,130 54.46 13.80 66.27
2020-02-10 2020-02-10 13G/A 11,756,120 12,096,797 2.90 8.30 2.47
2019-02-04 2019-02-04 13G/A 12,094,021 11,756,120 -2.79 8.10 -4.71
2018-01-25 2018-01-25 13G/A 10,711,760 12,094,021 12.90 8.50 2.41
2017-01-24 2017-01-24 13G/A 10,711,760 10,711,760 0.00 8.30 0.00
2017-01-23 2017-01-23 13G/A 7,778,349 10,711,760 37.71 8.30 36.07
2016-01-26 2016-01-26 13G/A 7,778,349 6.10
2015-01-30 2015-01-30 13G/A 7,421,617 5.90
2014-01-29 2014-01-29 13G 6,456,435 5.70

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 13,265,053 111,196 0.85 857,320 -3.16 0.0011
2026-02-12 2025-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 13,153,857 293,658 2.28 885,255 -6.14 0.0150
2025-11-12 2025-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 12,860,199 -339,833 -2.57 943,167 37.35 0.0165
2025-08-12 2025-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 13,200,032 -3,892,079 -22.77 686,666 -37.04 0.0131
2025-05-02 2025-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 17,092,111 -474,044 -2.70 1,090,648 29.86 0.0229
2025-02-07 2024-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 17,566,155 136,136 0.78 839,838 -15.82 0.0170
2024-11-13 2024-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 17,430,019 -189,918 -1.08 997,694 8.14 0.0209
2024-08-13 2024-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 17,619,937 -621,611 -3.41 922,580 24.33 0.0209
2024-05-10 2024-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,241,548 -389,415 -2.09 742,066 7.76 0.0173
2024-02-13 2023-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,630,963 512,348 2.83 688,600 -0.51 0.0176
2023-11-13 2023-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 18,118,615 -485,878 -2.61 692,131 3.14 0.0199
2023-08-11 2023-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 18,604,493 458,641 2.53 671,064 -3.16 0.0185
2023-05-12 2023-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,145,852 -69,874 -0.38 692,990 -33.14 0.0204
2023-02-13 2022-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,215,726 16,093 0.09 1,036,475 44.03 0.0325
2022-11-14 2022-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 18,199,633 -181,772 -0.99 719,614 -11.02 0.0245
2022-08-12 2022-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 18,381,405 -1,288,820 -6.55 808,782 3.10 0.0259
2022-05-12 2022-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 19,670,225 230,362 1.18 784,449 0.35 0.0211
2022-02-10 2021-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 19,439,863 144,483 0.75 781,676 -0.42 0.0199
2021-11-09 2021-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 19,295,380 228,942 1.20 784,935 -9.34 0.0220
2021-08-11 2021-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 19,066,438 628,960 3.41 865,808 12.64 0.0241
2021-05-07 2021-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,437,478 -43,829 -0.24 768,660 -2.62 0.0226
2021-02-05 2020-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 18,481,307 5,272,072 39.91 789,337 127.38 0.0252
2020-11-06 2020-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 13,209,235 -24,071 -0.18 347,138 -2.16 0.0128
2020-08-14 2020-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 13,233,306 1,086,502 8.94 354,786 62.36 0.0142
2020-05-01 2020-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,146,804 50,007 0.41 218,520 1.89 0.0107
2020-02-13 2019-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,096,797 -907,741 -6.98 214,477 6.33 0.0082
2019-11-08 2019-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 13,004,538 379,410 3.01 201,701 -7.01 0.0085
2019-08-22 2019-06-30 13F/A-1 HALOZYME THERAPEUTICS COM 40637H109 12,625,128 929,980 7.95 216,900 15.19 0.0093
2019-08-13 2019-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 12,625,128 929,980 216,900
2019-05-09 2019-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,695,148 -60,972 -0.52 188,292 9.48 0.0084
2019-02-08 2018-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,756,120 -125,406 -1.06 171,991 -20.33 0.0087
2018-11-09 2018-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 11,881,526 -360,905 -2.95 215,886 4.53 0.0093
2018-08-09 2018-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 12,242,431 659,763 5.70 206,530 -8.98 0.0095
2018-05-09 2018-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,582,668 -511,353 -4.23 226,905 -7.40 0.0108
2018-02-09 2017-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 12,094,021 -70,354 -0.58 245,025 15.96 0.0117
2017-11-14 2017-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 12,164,375 568,875 4.91 211,295 42.14 0.0107
2017-08-10 2017-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 11,595,500 532,658 4.81 148,652 3.68 0.0079
2017-05-12 2017-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 11,062,842 10,913,199 7,292.82 143,374 9,600.54 0.0079
2017-02-10 2016-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 149,643 127,787 584.68 1,478 459.85 0.0021
2016-11-08 2016-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 21,856 795 3.77 264 45.05 0.0004
2016-08-10 2016-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 21,061 13,991 197.89 182 171.64 0.0003
2016-05-10 2016-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 7,070 3,993 129.77 67 26.42 0.0001
2016-02-11 2015-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,077 -732 -19.22 53 1.92 0.0001
2015-11-13 2015-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,809 749 24.48 52 -24.64 0.0001
2015-08-07 2015-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,060 -178 -5.50 69 46.81 0.0001
2015-05-13 2015-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,238 0 0.00 47 51.61 0.0001
2015-02-09 2014-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,238 0 0.00 31 6.90 0.0000
2014-10-29 2014-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,238 0 0.00 29 -9.37 0.0000
2014-08-06 2014-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,238 -17 -0.52 32 -21.95 0.0000
2014-05-02 2014-03-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,255 135 4.33 41 -12.77 0.0001
2014-02-12 2013-12-31 13F HALOZYME THERAPEUTICS COM 40637H109 3,120 -140 -4.29 47 30.56 0.0001
2013-11-12 2013-09-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,260 0 0.00 36 38.46 0.0001
2013-08-13 2013-06-30 13F HALOZYME THERAPEUTICS COM 40637H109 3,260 3,260 26 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.